News stories about Teladoc (NYSE:TDOC) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teladoc earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news stories about the health services provider an impact score of 47.0222905241073 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

Teladoc (TDOC) opened at 30.90 on Monday. The firm’s 50-day moving average is $34.47 and its 200 day moving average is $26.96. The stock’s market capitalization is $1.69 billion. Teladoc has a 1-year low of $13.49 and a 1-year high of $36.90.

Teladoc (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.02. Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The firm had revenue of $44.60 million during the quarter, compared to analyst estimates of $44.39 million. During the same period in the prior year, the company posted ($0.38) earnings per share. The firm’s revenue for the quarter was up 68.3% compared to the same quarter last year. Equities analysts anticipate that Teladoc will post ($1.27) EPS for the current fiscal year.

A number of research firms recently weighed in on TDOC. Piper Jaffray Companies raised their target price on shares of Teladoc from $26.00 to $32.00 and gave the company an “overweight” rating in a report on Tuesday, April 11th. TheStreet raised shares of Teladoc from a “d” rating to a “c-” rating in a report on Thursday, April 13th. Zacks Investment Research lowered shares of Teladoc from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Chardan Capital raised their target price on shares of Teladoc from $28.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, May 9th. Finally, Robert W. Baird reissued a “buy” rating and issued a $28.00 target price on shares of Teladoc in a report on Tuesday, May 9th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $35.55.

TRADEMARK VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/07/teladoc-nysetdoc-receives-media-impact-rating-of-0-11.html.

In other Teladoc news, CEO Jason N. Gorevic sold 14,400 shares of the company’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $29.57, for a total value of $425,808.00. Following the completion of the sale, the chief executive officer now directly owns 822,961 shares in the company, valued at approximately $24,334,956.77. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Mark Hirschhorn sold 100,000 shares of the company’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $27.70, for a total value of $2,770,000.00. Following the completion of the sale, the vice president now owns 80,887 shares of the company’s stock, valued at $2,240,569.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 153,380 shares of company stock valued at $4,459,268. 5.94% of the stock is owned by company insiders.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.